BlueCrest Capital Management Ltd increased its stake in Pfizer, Inc. (NYSE:PFE) by 105.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 164,203 shares of the biopharmaceutical company’s stock after purchasing an additional 84,191 shares during the quarter. BlueCrest Capital Management Ltd’s holdings in Pfizer were worth $5,617,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Asset Planning Services Ltd. boosted its holdings in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the last quarter. Orrstown Financial Services Inc. boosted its holdings in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 612 shares during the last quarter. Cable Hill Partners LLC boosted its holdings in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 265 shares during the last quarter. Acropolis Investment Management LLC boosted its holdings in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 100 shares during the last quarter. Finally, Cohen Lawrence B purchased a new stake in Pfizer in the first quarter worth approximately $201,000. Institutional investors own 69.09% of the company’s stock.

In related news, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now directly owns 124,774 shares of the company’s stock, valued at $4,242,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Insiders have sold 426,291 shares of company stock worth $14,475,911 over the last three months. 0.06% of the stock is currently owned by insiders.

WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/10/bluecrest-capital-management-ltd-raises-position-in-pfizer-inc-pfe.html.

Several brokerages recently issued reports on PFE. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, August 2nd. Berenberg Bank set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, August 1st. Morgan Stanley restated a “neutral” rating and issued a $35.00 target price (down previously from $38.00) on shares of Pfizer in a report on Monday, June 12th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Finally, Citigroup Inc. cut shares of Pfizer from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. Pfizer presently has an average rating of “Hold” and a consensus target price of $37.61.

Shares of Pfizer, Inc. (NYSE PFE) traded up 0.32% during mid-day trading on Friday, reaching $34.10. 15,442,446 shares of the company’s stock were exchanged. The company’s 50 day moving average is $33.36 and its 200 day moving average is $33.49. The stock has a market capitalization of $202.80 billion, a PE ratio of 24.95 and a beta of 1.00. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $34.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the firm posted $0.64 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities research analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.